Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Feb 2018 Status changed from not yet recruiting to recruiting.
- 05 Dec 2017 Planned End Date changed from 3 Aug 2018 to 4 Sep 2018.
- 05 Dec 2017 Planned primary completion date changed from 29 Jun 2018 to 31 Jul 2018.